Hohnloser S, Zeiher A, Hust M H, Wollschläger H, Just H
Clin Cardiol. 1983 Mar;6(3):130-5. doi: 10.1002/clc.4960060306.
Flecainide acetate is a new class I antiarrhythmic agent which slows atrial, A-V nodal and ventricular conduction velocity, and prolongs refractoriness of these structures (Borchard et al., 1982; Hodess et al., 1979). Recent studies with oral flecainide therapy suggested its high potential for suppression of ventricular tachycardia in humans (Anderson et al., 1981; Duff et al., 1981; Hodges et al., 1982). Its favorable pharmacokinetics with an average plasma half-time of about 20 hours allows in most patients twice daily dosing (Duff et al., 1981). Usually, the drug seemed to be well tolerated and side-effects, such as blurred vision, could be resolved with smaller but still effective doses (Duff et al., 1981). Actually, the ideal antiarrhythmic agent which represents a high degree of effectiveness, a low level of toxicity, a wide therapeutic range, and a prolonged antiarrhythmic action does not exist (Dreifus and Ogawa, 1977). In this report we describe a patient with flecainide-induced aggravation of ventricular tachycardia necessitating resuscitation because of severe hemodynamic deterioration.
醋酸氟卡尼是一种新型的Ⅰ类抗心律失常药物，它可减慢心房、房室结和心室的传导速度，并延长这些结构的不应期（博查德等人，1982年；霍德斯等人，1979年）。近期关于口服氟卡尼治疗的研究表明，它在抑制人类室性心动过速方面具有很高的潜力（安德森等人，1981年；达夫等人，1981年；霍奇斯等人，1982年）。其良好的药代动力学特性，平均血浆半衰期约为20小时，使得大多数患者可以每日给药两次（达夫等人，1981年）。通常，该药物似乎耐受性良好，副作用如视力模糊等，可以通过较小但仍然有效的剂量得到缓解（达夫等人，1981年）。实际上，代表高度有效性、低毒性、宽治疗范围和延长抗心律失常作用的理想抗心律失常药物并不存在（德赖弗斯和小川，1977年）。在本报告中，我们描述了一名因氟卡尼导致室性心动过速加重，因严重血流动力学恶化而需要复苏的患者。
